For patients
As a patient, you cannot register directly for a consultation. Please have your family doctor, specialist refer you. If you have any questions, please use our contact form.
PSMA-PET with 18F-PSMA approved in Switzerland since October 2019. Compared to choline PET, PSMA PET has a significantly higher sensitivity for lymph node and distant metastases and, in contrast to choline PET, can also be used well for initial staging in prostate cancer.
The following indication is reimbursed by the health insurance:
Senior Attending Physician, Vice Director of Department, Department of Nuclear Medicine
Attending Physician, Department of Nuclear Medicine
Attending Physician with extended responsibilites, Department of Nuclear Medicine
Attending Physician with extended responsibilites, Department of Nuclear Medicine
Attending Physician with extended responsibilites, Department of Nuclear Medicine
As a patient, you cannot register directly for a consultation. Please have your family doctor, specialist refer you. If you have any questions, please use our contact form.
Simply assign your patient via registration form.
Medical information hotline: 08.00-18.00 o’clock: +41 44 255 15 02